The downstream VEGF effects via VEGF-PTPRZ interaction are not affected by anti-VEGF drugs, which may explain the resistance developed by certain tumor types (such as glioblastoma) to anti-angiogenic cancer therapies [261]. This evidence concerns the gene VEGFA and neoplasm.